Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Achieve Life Sciences (ACHV) Convertible Debt (2021 - 2026)

Achieve Life Sciences (ACHV) has disclosed Convertible Debt for 6 consecutive years, with $9.3 million as the latest value for Q1 2026.

  • Quarterly Convertible Debt rose 7.68% to $9.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $9.3 million through Mar 2026, up 7.68% year-over-year, with the annual reading at $11.2 million for FY2025, 13.7% up from the prior year.
  • Convertible Debt for Q1 2026 was $9.3 million at Achieve Life Sciences, down from $11.2 million in the prior quarter.
  • The five-year high for Convertible Debt was $16.2 million in Q3 2023, with the low at $8.7 million in Q1 2025.
  • Average Convertible Debt over 5 years is $11.8 million, with a median of $9.8 million recorded in 2024.
  • The sharpest move saw Convertible Debt tumbled 44.03% in 2024, then grew 13.7% in 2025.
  • Achieve Life Sciences' Convertible Debt stood at $15.8 million in 2022, then increased by 2.74% to $16.2 million in 2023, then tumbled by 39.26% to $9.8 million in 2024, then grew by 13.7% to $11.2 million in 2025, then fell by 16.66% to $9.3 million in 2026.
  • Per Business Quant, the three most recent readings for ACHV's Convertible Debt are $9.3 million (Q1 2026), $11.2 million (Q4 2025), and $8.7 million (Q3 2025).